trastuzumab

trastuzumab is a monoclonal antibody that interferes with the HER2/neu receptor, which is associated with breast cancer, particularly in patients with invasive ductal carcinoma and inflammatory breast cancer, as studied by Dennis Slamon and Axel Ullrich. The development of trastuzumab is attributed to the work of Genentech, a biotechnology company founded by Herbert Boyer and Robert Swanson, in collaboration with University of California, Los Angeles and University of California, San Francisco. Trastuzumab has been used in combination with chemotherapy and other targeted therapies, such as pertuzumab and lapatinib, to treat patients with metastatic breast cancer, as demonstrated in clinical trials conducted by National Cancer Institute and American Cancer Society.

● Introduction

Trastuzumab is used to treat patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, which accounts for approximately 20% of all breast cancer cases, as reported by the World Health Organization and International Agency for Research on Cancer. The introduction of trastuzumab has significantly improved the treatment outcomes for patients with HER2-positive breast cancer, as shown in studies published in the Journal of Clinical Oncology and New England Journal of Medicine. Trastuzumab has been approved by the US Food and Drug Administration and European Medicines Agency for use in combination with chemotherapy and other targeted therapies, such as docetaxel and carboplatin, as recommended by the National Comprehensive Cancer Network and European Society for Medical Oncology.

● Mechanism_of_action

Trastuzumab works by binding to the HER2/neu receptor on the surface of cancer cells, which inhibits the signaling pathways that promote cell proliferation and survival, as described by Robert Weinberg and Charles Sawyers. The binding of trastuzumab to the HER2/neu receptor also induces antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, which helps to eliminate cancer cells, as demonstrated in studies conducted by Stanford University and University of Pennsylvania. Trastuzumab has been shown to inhibit the signaling pathways mediated by PI3K/AKT and MAPK/ERK, which are involved in cell growth and survival, as reported by Harvard University and Massachusetts Institute of Technology.

● Medical_uses

Trastuzumab is used to treat patients with HER2-positive breast cancer, including those with early-stage breast cancer and metastatic breast cancer, as recommended by the American Society of Clinical Oncology and European Breast Cancer Conference. Trastuzumab has been shown to improve the overall survival and progression-free survival of patients with HER2-positive breast cancer, as demonstrated in clinical trials conducted by National Cancer Institute and European Organisation for Research and Treatment of Cancer. Trastuzumab is also used in combination with chemotherapy and other targeted therapies, such as pertuzumab and lapatinib, to treat patients with gastric cancer and gastroesophageal junction cancer, as reported by the Journal of Clinical Oncology and Lancet Oncology.

● Side_effects

Trastuzumab can cause several side effects, including cardiotoxicity, infusion reactions, and neutropenia, as reported by the US Food and Drug Administration and European Medicines Agency. The cardiotoxicity associated with trastuzumab is thought to be related to the inhibition of the HER2/neu receptor, which is involved in the regulation of cardiac function, as described by University of California, San Francisco and Duke University. Trastuzumab can also cause infusion reactions, including fever, chills, and hypotension, which can be managed with premedication and supportive care, as recommended by the National Comprehensive Cancer Network and European Society for Medical Oncology.

● History

Trastuzumab was first approved by the US Food and Drug Administration in 1998 for the treatment of patients with metastatic breast cancer, as reported by the New York Times and Wall Street Journal. The development of trastuzumab is attributed to the work of Genentech, a biotechnology company founded by Herbert Boyer and Robert Swanson, in collaboration with University of California, Los Angeles and University of California, San Francisco. Trastuzumab has since become a standard treatment for patients with HER2-positive breast cancer, as recommended by the American Society of Clinical Oncology and European Breast Cancer Conference.

● Pharmacology

Trastuzumab is a monoclonal antibody that is administered via intravenous infusion, as described by the US Food and Drug Administration and European Medicines Agency. The pharmacokinetics of trastuzumab have been studied in patients with breast cancer, as reported by the Journal of Clinical Pharmacology and European Journal of Clinical Pharmacology. Trastuzumab has a half-life of approximately 28 days, which allows for once-weekly or once-every-3-weeks dosing, as recommended by the National Comprehensive Cancer Network and European Society for Medical Oncology. The pharmacodynamics of trastuzumab have been studied in patients with HER2-positive breast cancer, as demonstrated in clinical trials conducted by National Cancer Institute and European Organisation for Research and Treatment of Cancer.

Category:Monoclonal antibodies